GLENMARK Glenmark Pharmaceuticals Q2 FY26 results (Jul–Sep 2025) and concall
Glenmark Pharma reported robust consolidated revenue growth in Q2 FY26, primarily driven by North America, while its India business faced a significant one-time decline due to GST-related disruptions. The company is transitioning into 'Glenmark 3.0,' aiming for zero gross debt by FY26 and strong return ratios, supported by the $700 million ISB 2001 deal proceeds. Management expressed confidence in the recovery of the India business and continued growth from its specialty and innovative pipeline.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue down 41.6%, net profit down 224.2% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 2,636 | 2,251 | 2,010 | 2,395 | 1,539 −42% |
| EBITDA | 779 | 494 | 341 | 728 | -178 −123% |
| Net profit | 595 | 414 | 148 | 330 | -739 −224% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
